Vol. 19 No. 2 (2015)
CARDIOLOGY

Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of antiarrhythmic drug therapy vs re-ablation

D. Losik
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
A. Romanov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
V. Shabanov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
S. Bairamova
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
A. Yakubov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
I. Stenin
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio
Ye. Pokushalov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, 15 Rechkunovskaya Str., 630055, Novosibirsk, Russian Federation
Bio

Published 2015-10-12

Keywords

  • atrial fibrillation,
  • ablation,
  • pulmonary veins,
  • implantable cardiac monitor,
  • antiarrhythmic drugs,
  • atrial fibrillation progression
  • ...More
    Less

How to Cite

Losik, D., Romanov, A., Shabanov, V., Bairamova, S., Yakubov, A., Stenin, I., & Pokushalov, Y. (2015). Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of antiarrhythmic drug therapy vs re-ablation. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(2), 84–92. https://doi.org/10.21688/1681-3472-2015-2-84-92

Abstract

Background. Treating atrial fibrillation (AF) with antiarrhythmic drugs (AAD) remains to be the first line therapy. Radiofrequency ablation is an alternative technique; however, in case of AF relapses, patients have to receive AAD.
Objective. The authors wanted to compare the efficacy of AAD and re-ablation in patients after a previous failed initial RF ablation.
Methods. 154 patients with AF persistent paroxysms after 3 months since the initial RF ablation were randomized into 2 groups. The first group received AAD therapy (77) and the second group underwent a re-ablation procedure (77). The patients were followed up for 3 years to assess the rhythm by means of an implanted cardiac monitor.
Results. At the end of follow-up, 18 (23%) patients in the AAD group and 3 (4%) patients in the re-ablation group progressed to persistent AF or increased AF progression by 30% as compared to preoperative data (p<0.01). In the AAD group AF% significantly increased as compared to that in the re-ablation group (at 36 months it was 18.8±11.4% vs 5.6±9.5% respectively (p<0.01). Moreover, 45 (58%) patients of the re-ablation group became AF/AT-free without antiarrhythmic drugs; in contrast, in the AAD group, only 9 (12%) of 77 patients were AF/AT-free (p<0.01). Multivariate logistic regression analysis allowed for finding out that the overage (more than 60 years) (OR 2.1; 95% confidence interval 1.1-4.1; p=0.04), AF anamnesis exceeding 5 years (OR 3.3; 95% confidence interval 1.7-6.3; p<0.01), arterial hypertension (OR 3.1; 95% confidence interval 5.1-6.3; p < 0.01) and diabetes mellitus (OR 4.6; 95% confidence interval 1.3-16.9; p=0.02) are inde-pendent AF progression predictors. When using HATCH score to assess AF progression, it was found out that a 2 points indicator cannot be considered as an independent predictor of AF progression (OR 2.3; 95% confidence interval -0.7-9.3; p=0.24).
Conclusion. The results demonstrate that AF RF re-ablation is more effective than AAD therapy for preventing AF progression.

References

  1. Benjamin E.J., Levy D., Vaziri S.M., D’Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study // Jama. 1994. Vol. 271. № 11. P. 840–844.
  2. Оганов Р.Г., Салимов В.А., Бокерия Л.А., и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий // Вестник аритмологии. 2010. № 59. С. 53–77.
  3. Артеменко С.Н., Романов А.Б., Шабанов В.В., Елесин Д.А., Стрельников А.Г., Камиев Р.Т., Лосик Д.В., Покушалов Е.А. Результаты радиочастотной изоляции устьев легочных вен в сочетании с аблацией ганглионарных сплетений у пациентов с пароксизмальной формой фибрилляции предсердий // Анналы аритмологии. 2011. Т. 8. № 4. С. 36–42.
  4. Артеменко С.Н., Романов А.Б., Туров А.Н., Шабанов В.В., Елесин Д.А., Якубов А.А., Стрельников А.Г., Камиев Р.Т., Лосик Д.В., Покушалов Е.А. Сравнительная оценка радиочастотной остиальной, антральной изоляции устьев легочных вен и аблации ганглионарных сплетений у пациентов с фибрилляцией предсердий // Вестник аритмологии. 2012. № 68. С. 14–20.
  5. Елесин Д.А., Романов А.Б., Туров А.Н., Шабанов В.В., Якубов А.А., Стенин И.Г., Лосик Д.В., Артеменко С.Н., Панфилов С.В., Покушалов Е.А. Радиочастотная аблация пароксизмальной и длительно персистирующей форм фибрилляции предсердий: 1-летний период наблюдения с помощью непрерывного подкожного мониторирования // Вестник аритмологии. 2011. № 63. С. 5–11.
  6. Шабанов В.В., Романов А.Б., Артёменко С.Н., Елесин Д.А., Стрельников А.Г., Лосик Д.В., Байрамова С.А., Покушалов Е.А. Определение оптимального подхода в лечении пациентов с ранними рецидивами фибрилляции предсердий после первой процедуры аблации // Патология кровообращения и кардиохирургия. 2013. № 1. С. 39–43.
  7. Gerstenfeld E.P., Marchlinski F.E. Mapping and ablation of left atrial tachycardias occurring after atrial fibrillation ablation // Heart Rhythm. 2007. Vol. 4. P. 65–72.
  8. Pappone C., Rosanio S., Augello G. et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized longterm study // J. Am. Coll. Cardiol. 2003. V.42. P.185–197.
  9. Calkins H., Kuck K.H., Cappato R., Brugada J., Camm A.J. et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society // Heart Rhythm. 2012. Vol. 9. P. 632–696.
  10. Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study // JACC. 2006. Vol. 48. P. 2340–2347.
  11. De Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis // J. Am. Coll. Cardiol. 2010. Vol. 55. P. 725–731.
  12. Kerr C.R., Humphries K.H., Talajic M., et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal AF: results from the Canadian Registry of AF // Am. Heart J. 2005. Vol. 149. P. 489–496.
  13. Jongnarangsin K., Suwanagool A., Chugh A., Crawford T., Good E., Pelosi F., Bogun F., Oral H., Morady F. Effect of catheter ablation on progression of paroxysmal atrial fibrillation // J. Cardiovasc. Electrophysiol. 2012. Vol. 23. P. 9–14.
  14. Nieuwlaat R., Prins M.H., Le Heuzey J.Y., et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation // Eur. Heart J. 2008. Vol. 29. P. 1181–9.
  15. Bhargava M., Di Biase L., et all. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study // Heart Rhythm. 2009. Vol. 6. P. 1403–1412.
  16. Abe Y., Fukunami M., Yamada T., Ohmori M., Shimonagata T., Kumagai K., Kim J., Sanada S., Hori M., Hoki N.. Prediction of transition to chronic atrial fibrillation in patients with paroxysmal atrial fibrillation by signal-averaged electrocardiography:a prospective study // Circulation. 1997. Vol. 96. P. 2612–2616.
  17. Kato T., Yamashita T., Sagara K., Linuma H., Fu L.T. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study // Circulation. 2004. Vol. 68. № 6. P. 568–72.
  18. Petersen P., Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation // Stroke. 1986. Vol. 17. P. 622–626.
  19. Saksena S., Hettrick D., Koehler J., Grammatico A., Padeletti L. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias // Am. Heart J. 2007. Vol. 154. № 5. P. 884–892.
  20. Kirchhof P., Breithardt G., Aliot E. et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference // Europace. 2013. Vol. 15. P. 1540–56.